Vividion Therapeutics and Bayer Strengthen Oncology Pipeline with Exclusive Rights to Clinical-Stage WRN Inhibitor VVD-214 Vividion Therapeutics, a clinical-stage biopharmaceutical company and a wholly owned, independently operated subsidiary of Bayer AG, announced today it has obtained exclusive global rights to…
Snke and Precision NeuroMed Partner to Accelerate Learning Cycles in Precision Brain Therapies Snke, a pioneering health tech company, and Precision NeuroMed (PNM), a clinical-stage biotechnology company advancing precision therapeutics for central nervous system (CNS) diseases, announced a partnership to streamline and…
OrsoBio to Present Preclinical and Clinical Data from its Mitochondrial Protonophore Portfolio at the American Diabetes Association’s 2026 Scientific Sessions OrsoBio, Inc. a clinical-stage biopharmaceutical company developing treatments for obesity and related metabolic disorders, announced new clinical and preclinical data…
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline Gilead Sciences, Inc. and Lakefront Biotherapeutics NV announced the successful completion of the previously announced acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases.…
Onchilles Pharma Doses First Patient in Phase 1/2 Clinical Trial of N17350 for Advanced Solid Tumors Onchilles Pharma, a clinical-stage biotechnology company pioneering next-generation cytotoxic therapeutics that harness the ELANE pathway, today announced that the first patient has been dosed…
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement Rallybio Corporation and Avenzo Therapeutics, Inc. a clinical-stage biotechnology company developing next-generation oncology therapies, announced that they have entered into a definitive…
Qurient Announces First Patient Dosed in Phase 2 Trial of Novel CDK7 Inhibitor Mocaciclib (Q901) for the treatment of HR-Positive Breast Cancer Qurient Co., Ltd. announced that the first patient has been dosed in a Phase 2 clinical study evaluating…
PanTher Completes Dose Escalation Phase in Non-Metastatic Pancreatic Cancer Phase 1b Trial and Appoints Tim Clackson to the Board of Directors PanTher Therapeutics a clinical-stage company redefining early cancer treatment with therapeutic implants administered directly at the tumor site, announced…
Secretome Therapeutics Announces $30 Million Series A Financing From RA Capital Management to Advance STM-01 for Duchenne-Associated Cardiomyopathy Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), announced the closing of a $30…
Archeus Technologies Doses First Patient in Phase 1 Study of ARC-706 and Companion Diagnostic ARC-166 for Metastatic Cancer Archeus Technologies, a clinical-stage company advancing a portfolio of differentiated small-molecule radiopharmaceutical therapies (RPTs) to address some of the most difficult-to-treat cancers,…
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model Turn Therapeutics Inc. a clinical-stage biotechnology company focused on developing localized therapies for inflammatory and infectious skin diseases, announced the publication of…
Sustained Therapeutics Presents Positive Phase 2 Data for ST-01 in Podium Presentation at the American Urological Association 2026 Annual Meeting Sustained Therapeutics, Inc. a clinical-stage urologic therapeutics company advancing differentiated therapies for underserved conditions, today presented additional data from its…